Clinical Trials

Knopp begins phase 2 trial for oral dexpramipexole in eosinophilic asthma

Knopp Biosciences LLC today announced the start of Phase 2 dose-ranging clinical trial in moderate-to-severe eosinophilic asthma.

Lynparza plus bevacizumab meets primary endpoint in PAOLA-1 trial

AstraZeneca and MSD said that Lynparza (olaparib) in combination with standard-of-care (SoC) bevacizumab succeeded in a phase 3 trial in advanced ovarian cancer by meeting the primary endpoint.

Lilly announces superiority of Taltz versus TREMFYA in IXORA-R trial

Eli Lilly and Company (NYSE: LLY) announced today Taltz (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).

Kedrion Biopharma announces enrollment of first patient in CARES10 trial

Kedrion Biopharma, an international specialist in the manufacture and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, today announced initiation of the CARES10 (Clinical Assessment of phaRmacokinetics, Efficacy, Safety of a 10% Ig) clinical study.

AstraZeneca’s Tagrisso meets secondary endpoint in phase III lung cancer study

AstraZeneca’s Tagrisso (osimertinib) has significantly improved overall survival (OS) in the patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer in the phase III Flaura trial.

Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer

Sesen Bio, a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported updated, preliminary primary and secondary endpoint data from the Company’s Phase 3 VISTA trial further supporting the strong benefit-risk profile of Vicinium for the potential treatment of patients with high-risk, bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC).

Lynparza phase III PROfound trial in HRR mutation-selected metastatic castration-resistant prostate cancer met primary endpoint

AstraZeneca and MSD (known as Merck & Co., Inc. inside the US and Canada) announced positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) who have a *homologous recombination repair gene mutation (HRRm) and have progressed on prior treatment with new hormonal anticancer treatments (e.g. enzalutamide and abiraterone).

HCL Technologies and Oracle Health Sciences collaborate to accelerate mHealth in clinical trials

HCL Technologies (HCL), a global technology company and a Platinum-Level member of Oracle Partner Network (OPN), and Oracle Health Sciences today announced a collaboration to help life sciences companies execute and scale the next generation of digital clinical trials to reduce the time and cost of drug development.

Lilly announces positive results for Emgality from CONQUER study

Eli Lilly announced that Emgality (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of Emgality in the preventive treatment of chronic and episodic migraine in patients with documented previous failures on two to four different standard-of-care migraine preventive medication categories, due to inadequate efficacy or for safety/tolerability reasons.